Curis (Nasdaq:CRIS) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CRIS 주식 개요

는 미국에서 인간 암 치료를 위한 신약 후보 물질을 발견하고 개발하는 생명공학 회사입니다.

CRIS 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

수익은 연간 37.35% 증가할 것으로 예상됩니다.

위험 분석

cash runway 경력이 1년 미만입니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $46M )

+ 1 더 많은 위험

Curis, Inc. 경쟁사

Carisma Therapeutics

NasdaqGM:CARM

US$42.8m

HCW Biologics

NasdaqGM:HCWB

US$38.6m

Cyclo Therapeutics

NasdaqCM:CYTH

US$33.5m

Nuo Therapeutics

OTCPK:AURX

US$22.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Curis
과거 주가
현재 주가	US$7.96
52주 최고치	US$18.00
52주 최저치	US$3.80
베타	3.44
11개월 변경	-26.26%
3개월 변경 사항	-26.30%
1년 변경 사항	-48.46%
33년 변화	-94.83%
5년 변화	-78.25%
IPO 이후 변화	-99.67%

최근 뉴스 및 업데이트

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03

Recent updates

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

Dec 08

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Dec 03

Curis, National Cancer Institute in development pact for anti-cancer agent

Nov 11

주주 수익률

	CRIS	US Biotechs	US 마켓
7D	-6.4%	-1.3%	0.4%
1Y	-48.5%	7.7%	22.9%

수익률 대 산업: CRIS 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: CRIS 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is CRIS's price volatile compared to industry and market?
CRIS volatility
CRIS Average Weekly Movement	12.8%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: CRIS 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: CRIS 의 주간 변동성( 13% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2000	49	Jim Dentzer	www.curis.com

는 미국에서 인간 암 치료를 위한 약물 후보를 발견하고 개발하는 생명공학 회사입니다. 임상 단계의 약물 후보로는 재발성 또는 불응성 또는 R/R, AML 및 고위험 골수이형성증후군 환자를 대상으로 한 1/2상 오픈 라벨 단일군 확장 시험 중인 경구용 저분자 IRAK4 키나제 억제제인 에마부서팁(Emavusertib)이 있습니다. 이 회사의 파이프라인에는 재발성 또는 불응성 미만성 거대 B세포 림프종 환자 치료를 위한 경구용 HDAC 및 PI3K 효소 이중 억제제인 피메피노스타트, PD-L1과 VISTA를 선택적으로 표적으로 하는 경구용 저분자 길항제인 CA-170, PD-L1과 TIM3의 분자 길항제인 저분자 TIM3/PD-L1인 CA-327도 포함되어 있습니다.

Curis, Inc. 기본 사항 요약

Curis 의 수익과 매출은 시가총액과 어떻게 비교하나요?
CRIS 기본 통계
시가총액	US$45.97m
수익(TTM)	-US$47.73m
수익(TTM)	US$9.81m

4.8x

P/S 비율

-1.0x

P/E 비율

CRIS 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
CRIS 손익 계산서(TTM)
수익	US$9.81m
수익 비용	US$40.21m
총 이익	-US$30.40m
기타 비용	US$17.33m
수익	-US$47.73m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-8.10
총 마진	-309.78%
순이익 마진	-486.45%
부채/자본 비율	424.0%

CRIS 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

CRIS 주식 개요

보상

위험 분석

Curis, Inc. 경쟁사

NasdaqGM:CARM

US$42.8m

NasdaqGM:HCWB

US$38.6m

NasdaqCM:CYTH

US$33.5m

OTCPK:AURX

US$22.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Curis, Inc. Announces Additional Data from Take Aim Leukemia Study

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 22% to US$77.40

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Recent updates

Curis, Inc. Announces Additional Data from Take Aim Leukemia Study

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 22% to US$77.40

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates upgraded to US$6.06 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 28%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

New major risk - Share price stability

Price target increased by 18% to US$180

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Price target increased to US$17.67

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis: Asymmetric Risk And Reward

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Consensus EPS estimates fall by 14%

Price target increased to US$15.75

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$14.20

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Consensus forecasts updated